Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug Discovery Foundation in New York City, a nonprofit group that supported earlier research of the GLP-1 receptor agonist liraglutide (Victoza, Saxenda) in Alzheimer's disease.

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet their main goal, sending shares of the Danish drugmaker down around 9% to their lowest level since July 2021.

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded,

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk.

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities," he said.

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Chris Hemsworth shares his family's experience with reminiscence therapy — unlocking old memories to help slow the progression of dementia — in the new documentary 'Chris Hemsworth: A Roadtrip to Remember.